Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

169
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
169
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

239
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
239
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

385
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
385
Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

348
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
348
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

210
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
210
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

188
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
188

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Five-Year Outcomes and Disease Trajectories in Moderate-to-Severe Ulcerative Colitis: A Korean Multicenter Inception Cohort.

Journal of gastroenterology and hepatology·2026
Same author

Epidemiological Trends in Inflammatory Bowel Disease in Korea: Age-Related Shifts and Urban-Rural Disparities in a Nationwide Study, 2004-2015.

Yonsei medical journal·2026
Same author

[Advanced Combination Therapy in Inflammatory Bowel Disease].

The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi·2026
Same author

Clinical Factors Associated With Endoscopic Decompression Failure and Recurrent Sigmoid Volvulus: A Retrospective Cohort Study.

Journal of gastroenterology and hepatology·2026
Same author

Ten-Year Trend in 5-Aminosalicylic Acid Prescription Patterns and Treatment Outcomes in Patients with Ulcerative Colitis: An Analysis of Korean Health Insurance Data.

Digestive diseases and sciences·2025
Same author

<i>Bacteroides fragilis</i> Promotes Mesenchymal Subtype in Colorectal Cancer.

Cancers·2025
Same journal

In Search of Adaptive-Like Features of NK Cells Co-Expressing NKG2C and NKG2A.

Immune network·2026
Same journal

Immunosenescence and Cancer: Cellular Aging Programs That Reshape Antitumor Immunity.

Immune network·2026
Same journal

Complement Anaphylatoxin C5a-Induced Mouse Lymphatic Functions Modulate Interactions Between Endothelial Cells and T Lymphocytes.

Immune network·2026
Same journal

Defining PI3K Signaling as a Key Regulator of Molecular Heterogeneity and Inflammation in Glomerular Lupus Nephritis.

Immune network·2026
Same journal

Beyond Perineural Drainage: Revisiting the Olfactory Nerve as an Active Immunological Interface During Neuroinflammation.

Immune network·2026
Same journal

Cigarette Smoke Induces the Pro-inflammatory Response of Lung Macrophages via Activation of the IL-33/ST2-Dependent Pathway.

Immune network·2026
See all related articles

Related Experiment Video

Updated: Aug 14, 2025

Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach
08:24

Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach

Published on: May 2, 2018

19.7K

Microbial Modulation in Inflammatory Bowel Diseases.

Jongwook Yu1, Jae Hee Cheon1

  • 1Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, Seoul 03722, Korea.

Immune Network
|January 11, 2023
PubMed
Summary
This summary is machine-generated.

Altering gut microbiota through interventions like antibiotics or fecal transplants may help manage inflammatory bowel diseases (IBD). Research explores these microbial modulation strategies for IBD treatment and understanding its development.

Keywords:
AntibioticsDysbiosisFecal microbiota transplantationInflammatory bowel diseasesMicrobiotaProbiotics

More Related Videos

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
07:34

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Published on: December 16, 2021

2.6K
Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells
06:57

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Published on: September 18, 2016

9.1K

Related Experiment Videos

Last Updated: Aug 14, 2025

Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach
08:24

Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach

Published on: May 2, 2018

19.7K
Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
07:34

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Published on: December 16, 2021

2.6K
Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells
06:57

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Published on: September 18, 2016

9.1K

Area of Science:

  • Gastroenterology and Microbiology
  • Inflammatory Bowel Diseases (IBD) Research

Background:

  • Gut dysbiosis, an imbalance in the intestinal microbiota, is a key characteristic of inflammatory bowel diseases (IBD).
  • The exact cause-and-effect relationship between IBD and gut dysbiosis is still under investigation.
  • Modulating the gut microbiota is being explored as a therapeutic strategy for IBD management.

Purpose of the Study:

  • To review existing research on microbial modulation as a therapeutic approach for IBD.
  • To examine the significance of these interventions in the pathogenesis of IBD.

Main Methods:

  • Review of studies employing antibiotics, probiotics (with or without prebiotics), and fecal microbiota transplantation (FMT) for IBD.
  • Analysis of the impact of these interventions on the gut microbiota ecosystem.
  • Examination of the role of microbial modulation in IBD development.

Main Results:

  • Various methods like antibiotics, probiotics, and FMT are used to modulate the gut microbiota in IBD.
  • The gut microbiota is a complex community, and specific microbial changes with different treatments are not extensively studied.
  • Limited studies exist on the precise effects of each therapeutic option on gut microbiota composition in IBD.

Conclusions:

  • Microbial modulation presents a potential therapeutic avenue for IBD.
  • Further research is needed to understand the specific effects of different interventions on the gut microbiota and their role in IBD pathogenesis.